ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On June 28, 2017 we announced results from clinical study
AP-LTX-401, a randomized, fasted, crossover design
pharmacokinetic study testing our LIMITx formulation LTX-04P3 in
healthy adult subjects.
A press release regarding the foregoing is attached as Exhibit
99.1.
| Item 9.01. | Financial Statements and Exhibits |
| Exhibit Number | Description |
| 99.1 | Press Release dated June 28, 2017 |
ACURA PHARMACEUTICALS, INC ExhibitEX-99.1 2 v469879_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology *** Peak blood levels of abused LIMITx doses can be reduced up to 65% *** PALATINE,…To view the full exhibit click here About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.